Enzon Pharmaceuticals Stock Current Valuation
| ENZNDelisted Stock | USD 0.20 0.01 5.26% |
Valuation analysis of Enzon Pharmaceuticals helps investors to measure Enzon Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Enzon Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Enzon Pharmaceuticals is based on 3 months time horizon. Increasing Enzon Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Enzon otc stock is determined by what a typical buyer is willing to pay for full or partial control of Enzon Pharmaceuticals. Since Enzon Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enzon OTC Stock. However, Enzon Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.2 | Real 0.16 | Hype 0.2 |
The intrinsic value of Enzon Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enzon Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enzon Pharmaceuticals helps investors to forecast how Enzon otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enzon Pharmaceuticals more accurately as focusing exclusively on Enzon Pharmaceuticals' fundamentals will not take into account other important factors: Enzon Pharmaceuticals OTC Stock Current Valuation Analysis
Enzon Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Enzon Pharmaceuticals Current Valuation | 17.63 M |
Most of Enzon Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Enzon Pharmaceuticals has a Current Valuation of 17.63 M. This is 99.88% lower than that of the Biotechnology sector and 99.62% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.89% higher than that of the company.
Enzon Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzon Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Enzon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enzon Pharmaceuticals by comparing valuation metrics of similar companies.Enzon Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Enzon Fundamentals
| Return On Equity | -0.016 | ||||
| Return On Asset | -0.0138 | ||||
| Operating Margin | (36.28) % | ||||
| Current Valuation | 17.63 M | ||||
| Shares Outstanding | 74.21 M | ||||
| Shares Owned By Insiders | 10.70 % | ||||
| Shares Owned By Institutions | 48.58 % | ||||
| Number Of Shares Shorted | 259.38 K | ||||
| Price To Earning | 1.52 X | ||||
| Price To Book | 7.41 X | ||||
| Price To Sales | 669.36 X | ||||
| Revenue | 701 K | ||||
| Gross Profit | 701 K | ||||
| EBITDA | (469 K) | ||||
| Net Income | (469 K) | ||||
| Cash And Equivalents | 46.79 M | ||||
| Cash Per Share | 0.63 X | ||||
| Debt To Equity | 1.46 % | ||||
| Current Ratio | 125.26 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (501 K) | ||||
| Short Ratio | 1.71 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 14.0 | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 19.72 M | ||||
| Total Asset | 47.75 M | ||||
| Retained Earnings | (75.61 M) | ||||
| Working Capital | 6.98 M | ||||
| Current Asset | 11.78 M | ||||
| Current Liabilities | 4.8 M | ||||
| Z Score | -1.4 | ||||
| Annual Yield | 0.65 % | ||||
| Net Asset | 47.75 M |
About Enzon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enzon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Enzon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enzon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Enzon OTC Stock
The ability to find closely correlated positions to Enzon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enzon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enzon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enzon Pharmaceuticals to buy it.
The correlation of Enzon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enzon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enzon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enzon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation. Note that the Enzon Pharmaceuticals information on this page should be used as a complementary analysis to other Enzon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Enzon OTC Stock
If you are still planning to invest in Enzon Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enzon Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |